Palo Alto, CA, United States of America

Mallesh Pandrala

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignees: Leland Stanford Junior University, The United States Government as Represented by the Department of Veterans Affairs. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Mallesh Pandrala

Introduction

Mallesh Pandrala is an accomplished inventor based in Palo Alto, California. He has made significant contributions to the field of inflammatory diseases through his innovative research and development of small molecule antagonists.

Latest Patents

Mallesh holds a patent for "Small molecule CMKLR1 antagonists in inflammatory disease." This patent focuses on the use of α-NETA analogs for the treatment of inflammatory diseases. His work in this area demonstrates his commitment to advancing medical science and improving patient outcomes.

Career Highlights

Throughout his career, Mallesh has worked with prestigious institutions, including Leland Stanford Junior University and the United States Government as represented by the Department of Veterans Affairs. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Mallesh has collaborated with notable colleagues such as Sanjay Malhotra and Vineet Kumar. These partnerships have further enriched his research and expanded the impact of his inventions.

Conclusion

Mallesh Pandrala's contributions to the field of inflammatory diseases through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to inspire advancements in medical research and treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…